SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Suhrbier A, Jaffar Bandjee MC, Gasque P. Arthritogenic alphaviruses: an overview. Nature Rev Rheumatol 2012; 8: 4209.
  • 2
    Jaffar-Bandjee MC, Ramful D, Gauzere BA, Hoarau JJ, Krejbich-Trotot P, Robin S, et al. Emergence and clinical insights into the pathology of chikungunya virus infection. Expert Rev Anti Infect Ther 2010; 8: 98796.
  • 3
    Suhrbier A, Mahalingam S. The immunobiology of viral arthritides. Pharmacol Ther 2009; 124: 3018.
  • 4
    Labadie K, Larcher T, Joubert C, Mannioui A, Delache B, Brochard P, et al. Chikungunya disease in nonhuman primates involves long-term viral persistence in macrophages. J Clin Invest 2010; 120: 894906.
  • 5
    Hoarau JJ, Jaffar Bandjee MC, Krejbich Trotot P, Das T, Li-Pat-Yuen G, Dassa B, et al. Persistent chronic inflammation and infection by chikungunya arthritogenic alphavirus in spite of a robust host immune response. J Immunol 2010; 184: 591427.
  • 6
    Suhrbier A, La Linn M. Clinical and pathologic aspects of arthritis due to Ross River virus and other alphaviruses. Curr Opin Rheumatol 2004; 16: 3749.
  • 7
    Akahata W, Yang ZY, Andersen H, Sun S, Holdaway HA, Kong WP, et al. A virus-like particle vaccine for epidemic chikungunya virus protects nonhuman primates against infection. Nat Med 2010; 16: 3348.
  • 8
    Warter L, Lee CY, Thiagarajan R, Grandadam M, Lebecque S, Lin RT, et al. Chikungunya virus envelope-specific human monoclonal antibodies with broad neutralization potency. J Immunol 2011; 186: 325864.
  • 9
    De Lamballerie X, Boisson V, Reynier JC, Enault S, Charrel RN, Flahault A, et al. On chikungunya acute infection and chloroquine treatment. Vector Borne Zoonotic Dis 2008; 8: 8379.
  • 10
    Gardner J, Anraku I, Le TT, Larcher T, Major L, Roques P, et al. Chikungunya virus arthritis in adult wild-type mice. J Virol 2010; 84: 802132.
  • 11
    Zaid A, Rulli NE, Rolph MS, Suhrbier A, Mahalingam S. Disease exacerbation by etanercept in a mouse model of alphaviral arthritis and myositis. Arthritis Rheum 2011; 63: 48891.
  • 12
    Mylonas AD, Harley D, Purdie DM, Pandeya N, Vecchio PC, Farmer JF, et al. Corticosteroid therapy in an alphaviral arthritis. J Clin Rheumatol 2004; 10: 32630.
  • 13
    Padmakumar B, Jayan JB, Menon R, Kottarathara AJ. Clinical profile of chikungunya sequelae, association with obesity and rest during acute phase. Southeast Asian J Trop Med Public Health 2010; 41: 8591.
  • 14
    Buch MH, Emery P. New therapies in the management of rheumatoid arthritis. Curr Opin Rheumatol 2011; 23: 24551.
  • 15
    Bonilla-Hernan MG, Miranda-Carus ME, Martin-Mola E. New drugs beyond biologics in rheumatoid arthritis: the kinase inhibitors. Rheumatology (Oxford) 2011; 50: 154250.
  • 16
    Singh JA, Wells GA, Christensen R, Tanjong Ghogomu E, Maxwell L, Macdonald JK, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011:CD008794.
  • 17
    Bax M, van Heemst J, Huizinga TW, Toes RE. Genetics of rheumatoid arthritis: what have we learned? Immunogenetics 2011; 63: 45966.
  • 18
    Scheinecker C, Smolen JS. Rheumatoid arthritis in 2010: from the gut to the joint. Nat Rev Rheumatol 2011; 7: 735.
  • 19
    Morrison TE, Whitmore AC, Shabman RS, Lidbury BA, Mahalingam S, Heise MT. Characterization of Ross River virus tropism and virus-induced inflammation in a mouse model of viral arthritis and myositis. J Virol 2006; 80: 73749.
  • 20
    Lidbury BA, Simeonovic C, Maxwell GE, Marshall ID, Hapel AJ. Macrophage-induced muscle pathology results in morbidity and mortality for Ross River virus-infected mice. J Infect Dis 2000; 181: 2734.
  • 21
    Seay AR, Griffin DE, Johnson RT. Experimental viral polymyositis: age dependency and immune responses to Ross River virus infection in mice. Neurology 1981; 31: 65660.
  • 22
    Ungethuem U, Haeupl T, Witt H, Koczan D, Krenn V, Huber H, et al. Molecular signatures and new candidates to target the pathogenesis of rheumatoid arthritis. Physiol Genomics 2010; 42A: 26782.
  • 23
    Geurts J, Joosten LA, Takahashi N, Arntz OJ, Gluck A, Bennink MB, et al. Computational design and application of endogenous promoters for transcriptionally targeted gene therapy for rheumatoid arthritis. Mol Ther 2009; 17: 187787.
  • 24
    Madsen L, Labrecque N, Engberg J, Dierich A, Svejgaard A, Benoist C, et al. Mice lacking all conventional MHC class II genes. Proc Natl Acad Sci U S A 1999; 96: 1033843.
  • 25
    Kasturi SP, Skountzou I, Albrecht RA, Koutsonanos D, Hua T, Nakaya HI, et al. Programming the magnitude and persistence of antibody responses with innate immunity. Nature 2011; 470: 5437.
  • 26
    Ling ZQ, Wang Y, Mukaisho K, Hattori T, Tatsuta T, Ge MH, et al. Novel statistical framework to identify differentially expressed genes allowing transcriptomic background differences. Bioinformatics 2010; 26: 14316.
  • 27
    Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005; 102: 1554550.
  • 28
    Rudd PA, Wilson J, Gardner J, Larcher T, Babarit C, Le TT, et al. Interferon response factors 3 and 7 protect against chikungunya virus hemorrhagic fever and shock. J Virol 2012; 86: 988898.
  • 29
    Gorchakov R, Frolova E, Frolov I. Inhibition of transcription and translation in Sindbis virus-infected cells. J Virol 2005; 79: 9397409.
  • 30
    Krejbich-Trotot P, Denizot M, Hoarau JJ, Jaffar-Bandjee MC, Das T, Gasque P. Chikungunya virus mobilizes the apoptotic machinery to invade host cell defenses. FASEB J 2011; 25: 31425.
  • 31
    Pankla R, Buddhisa S, Berry M, Blankenship DM, Bancroft GJ, Banchereau J, et al. Genomic transcriptional profiling identifies a candidate blood biomarker signature for the diagnosis of septicemic melioidosis. Genome Biol 2009; 10: R127.
  • 32
    Hammamieh R, Barmada M, Ludwig G, Peel S, Koterski N, Jett M. Blood genomic profiles of exposures to Venezuelan equine encephalitis in Cynomolgus macaques (Macaca fascicularis). Virol J 2007; 4: 82.
  • 33
    Chao CC, Chen SJ, Adamopoulos IE, Davis N, Hong K, Vu A, et al. Anti-IL-17A therapy protects against bone erosion in experimental models of rheumatoid arthritis. Autoimmunity 2011; 44: 24352.
  • 34
    Yamada H, Nakashima Y, Okazaki K, Mawatari T, Fukushi J, Oyamada A, et al. Preferential accumulation of activated Th1 cells not only in rheumatoid arthritis but also in osteoarthritis joints. J Rheumatol 2011; 38: 156975.
  • 35
    Snir O, Rieck M, Gebe JA, Yue BB, Rawlings CA, Nepom G, et al. Identification and functional characterization of T cells reactive to citrullinated vimentin in HLA–DRB1*0401–positive humanized mice and rheumatoid arthritis patients. Arthritis Rheum 2011; 63: 287383.
  • 36
    Wauquier N, Becquart P, Nkoghe D, Padilla C, Ndjoyi-Mbiguino A, Leroy EM. The acute phase of chikungunya virus infection in humans is associated with strong innate immunity and T CD8 cell activation. J Infect Dis 2011; 204: 11523.
  • 37
    Bouquillard E, Combe B. A report of 21 cases of rheumatoid arthritis following chikungunya fever: a mean follow-up of two years. Joint Bone Spine 2009; 76: 6547.
  • 38
    Ganu MA, Ganu AS. Post-chikungunya chronic arthritis—our experience with DMARDs over two year follow up. J Assoc Physicians India 2011; 59: 836.
  • 39
    Chopra A, Anuradha V, Lagoo-Joshi V, Kunjir V, Salvi S, Saluja M. Chikungunya virus aches and pains: an emerging challenge. Arthritis Rheum 2008; 58: 29212.
  • 40
    Mylonas AD, Brown AM, Carthew TL, McGrath B, Purdie DM, Pandeya N, et al. Natural history of Ross River virus-induced epidemic polyarthritis. Med J Aust 2002; 177: 35660.
  • 41
    Tak PP, Kalden JR. Advances in rheumatology: new targeted therapeutics. Arthritis Res Ther 2011; 13 Suppl 1: S5.
  • 42
    Chow A, Her Z, Ong EK, Chen JM, Dimatatac F, Kwek DJ, et al. Persistent arthralgia induced by chikungunya virus infection is associated with interleukin-6 and granulocyte macrophage colony-stimulating factor. J Infect Dis 2011; 203: 14957.
  • 43
    Nasonova VA, Lukina GV, Sigidin Ia A. Neutralisation of interferon gamma—a new trend in therapy of rheumatoid arthritis. Ter Arkh 2008; 80: 307. In Russian.
  • 44
    Lidbury BA, Rulli NE, Suhrbier A, Smith PN, McColl SR, Cunningham AL, et al. Macrophage-derived proinflammatory factors contribute to the development of arthritis and myositis after infection with an arthrogenic alphavirus. J Infect Dis 2008; 197: 158593.
  • 45
    Rulli NE, Rolph MS, Srikiatkhachorn A, Anantapreecha S, Guglielmotti A, Mahalingam S. Protection from arthritis and myositis in a mouse model of acute chikungunya virus disease by bindarit, an inhibitor of monocyte chemotactic protein-1 synthesis. J Infect Dis 2011; 204: 102630.
  • 46
    Lebre MC, Vergunst CE, Choi IY, Aarrass S, Oliveira AS, Wyant T, et al. Why CCR2 and CCR5 blockade failed and why CCR1 blockade might still be effective in the treatment of rheumatoid arthritis. PLoS ONE 2011; 6: e21772.
  • 47
    Woodruff TM, Nandakumar KS, Tedesco F. Inhibiting the C5–C5a receptor axis. Mol Immunol 2011; 48: 163142.
  • 48
    Morrison TE, Simmons JD, Heise MT. Complement receptor 3 promotes severe Ross River virus-induced disease. J Virol 2008; 82: 1126372.
  • 49
    Martinez-Lostao L, Garcia-Alvarez F, Basanez G, Alegre-Aguaron E, Desportes P, Larrad L, et al. Liposome-bound APO2L/TRAIL is an effective treatment in a rabbit model of rheumatoid arthritis. Arthritis Rheum 2010; 62: 227282.
  • 50
    Sozzani S, Bosisio D, Scarsi M, Tincani A. Type I interferons in systemic autoimmunity. Autoimmunity 2010; 43: 196203.